Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study

J Am Acad Dermatol. 2024 Jun;90(6):1268-1271. doi: 10.1016/j.jaad.2024.01.070. Epub 2024 Feb 9.

¹ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; University of Illinois College of Medicine, Chicago, Illinois.
³ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
⁴ Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
⁵ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: stchen@partners.org.

No abstract available

Keywords: dermatologic immune-related adverse events; immune checkpoint inhibitor; immunotherapy; oncology.

Publication types